Author name: Leonardo Arias

The insurer will cut its MA payment timelines in half for select providers in Oklahoma, Idaho, Minnesota and Missouri in an effort to provide relief to rural hospitals.

Buying vaccine biotech Dynavax was an easy choice for Sanofi despite antivaccine moves by the Trump administration.

At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of the HIV market and its plans for business development.

Workers at the National Institute for Occupational Safety and Health affected by the layoffs last spring received emails yesterday that their reduction-in-force notices have been revoked. Hundreds of NIOSH employees had been let go.

The next Medical Device User Fee Amendments, which will set how much the FDA can raise from the industry in fees over a five-year period, are expected to go to Congress this year.

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.

  Cuando hace años un reconocido jugador se enfrentó por primera vez a una plataforma online, y siempre surgía la misma duda: ¿realmente entendemos qué es el azar cuando todo pasa en una pantalla y un servidor decide todo en segundos? Antes, en los casinos …

Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, setting both revenue and R&D targets through the end of the decade.

Conforme la NASA se acerca al lanzamiento espacial que marcará el inicio de la misión tripulada Artemis 2 a la Luna, la agencia se prepara para culminar las tareas de integración y diversas pruebas y ensayos relacionados con el futuro lanzamiento espacial.   La primera mi …

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient access improves.